Resistance to RAF inhibitors such as vemurafenib and dabrafenib is a major clinical problem in the treatment of melanoma. Patients withmutant BRAFmelanoma that progress on RAF inhibitors have limited treatment options, and drug removal from resistant tumors may elicit multiple effects. A frequent mechanism of resistance to RAF inhibitors is caused by expression of mutant BRAF splice variants. RAF inhibitor–resistant cell lines, generated in vivo, were tested as to whether or notmutant BRAF splice variants confer a fitness advantage in the presence of RAF inhibitor. Critically, cells expressing distinct mutant BRAF splice variants growmore efficiently in vitro and in vivo in the presence of the vemurafenib analog, PLX4720, compared with in t...
PURPOSE: About 65% to 70% of melanomas harbor a mutation in v-raf murine sarcoma viral oncogene homo...
SummaryBRAF is an attractive target for melanoma drug development. However, resistance to BRAF inhib...
Abstract Blocking oncogenic signaling induced by the BRAF V600E mutation is a promising approach for...
Resistance to RAF inhibitors such as vemurafenib and dabrafenib is a major clinical problem in the t...
The serine/threonine kinase, BRAF, is mutated in 7% of cancers and 50% of melanomas. The majority of...
B-RAF is the most frequently mutated protein kinase in human cancers. The finding that oncogenic mut...
B-RAF is the most frequently mutated protein kinase in human cancers. The finding that oncogenic mut...
Activated RAS promotes dimerization of members of the RAF kinase family. ATP-competitive RAF inhibit...
The identification of BRAF V600E as a driving mutation in approximately 50% of melanoma and the subs...
Mutations in the serine/threonine kinase BRAF are found in more than 60 % of melanomas. The most pre...
The Food and Drug Administration (FDA) has approved MAPK inhibitors as a treatment for melanoma pati...
RAF and MEK inhibitors are effective in BRAF-mutant melanoma but not in BRAF-mutant colorectal cance...
Since the discovery of BRAF mutations in over 50% of melanomas, various small molecule inhibitors ag...
PURPOSE: About 65% to 70% of melanomas harbor a mutation in v-raf murine sarcoma viral oncogene homo...
RAF inhibitors have the unique property of transactivating RAS-dependent RAF dimers in most cells bu...
PURPOSE: About 65% to 70% of melanomas harbor a mutation in v-raf murine sarcoma viral oncogene homo...
SummaryBRAF is an attractive target for melanoma drug development. However, resistance to BRAF inhib...
Abstract Blocking oncogenic signaling induced by the BRAF V600E mutation is a promising approach for...
Resistance to RAF inhibitors such as vemurafenib and dabrafenib is a major clinical problem in the t...
The serine/threonine kinase, BRAF, is mutated in 7% of cancers and 50% of melanomas. The majority of...
B-RAF is the most frequently mutated protein kinase in human cancers. The finding that oncogenic mut...
B-RAF is the most frequently mutated protein kinase in human cancers. The finding that oncogenic mut...
Activated RAS promotes dimerization of members of the RAF kinase family. ATP-competitive RAF inhibit...
The identification of BRAF V600E as a driving mutation in approximately 50% of melanoma and the subs...
Mutations in the serine/threonine kinase BRAF are found in more than 60 % of melanomas. The most pre...
The Food and Drug Administration (FDA) has approved MAPK inhibitors as a treatment for melanoma pati...
RAF and MEK inhibitors are effective in BRAF-mutant melanoma but not in BRAF-mutant colorectal cance...
Since the discovery of BRAF mutations in over 50% of melanomas, various small molecule inhibitors ag...
PURPOSE: About 65% to 70% of melanomas harbor a mutation in v-raf murine sarcoma viral oncogene homo...
RAF inhibitors have the unique property of transactivating RAS-dependent RAF dimers in most cells bu...
PURPOSE: About 65% to 70% of melanomas harbor a mutation in v-raf murine sarcoma viral oncogene homo...
SummaryBRAF is an attractive target for melanoma drug development. However, resistance to BRAF inhib...
Abstract Blocking oncogenic signaling induced by the BRAF V600E mutation is a promising approach for...